ACSL4 and metabolic dysfunction-associated steatotic liver disease: Abemaciclib, a cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitor, selectively inhibits ACSL4 and can significantly improve most NAFLD symptoms in a mouse model of NAFLD by promoting fatty-acid β-oxidation at low doses [128].